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Background: Inflammation plays an essential role in the development and complications 
of atherosclerosis plaques, including acute coronary syndromes (ACS). Indeed, previous 
reports have shown that within the coronary circulation of ACS patients, several soluble 
mediators are released. Moreover, it has been demonstrated that endothelial dysfunction 
might play an important role in atherosclerosis as well as ACS pathophysiology. However, 
the mechanisms by which these soluble mediators might affect endothelial functions are 
still largely unknown. We have evaluated whether soluble mediators contained in serum 
from coronary circulation of ACS patients might promote changes of gene profile in 
human coronary endothelial cells (HCAECs).
Methods: HCAECs were stimulated in  vitro for 12  h with serum obtained from the 
coronary sinus (CS) and the aorta (Ao) of ACS patients; stable angina (SA) patients 
served as controls. Gene expression profiles of stimulated cells were evaluated by 
microarray and real-time PCR.
results: HCAECs stimulated with serum from CS of ACS patients showed a significant 
change (upregulation and downregulation) in gene expression profile as compared with 
cells stimulated with serum from CS of SA patients. Moreover, ad  hoc sub analysis 
indicated the upregulation of Th-17/IL-17 pathway-related genes.
conclusion: This study demonstrates that, in ACS patients, the chemical mediators 
released in the coronary circulation might be able to perturb coronary endothelial cells 
(ECs) modifying their gene profile. These modified ECs, through downregulation of 
protective gene and, mainly, through upregulation of gene able to modulate the Th-17/
IL-17 pathway, might play a key role in progression of coronary atherosclerosis and in 
developing future acute events.
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inTrODUcTiOn
Adaptive immune responses are involved in all stages of ath-
erosclerotic plaque development (1). Specifically, cytokines and 
cells belonging to the immunity promote endothelial dysfunc-
tion, a phenomenon that plays a crucial role at the beginning 
of the atherosclerotic plaque formation. Then, immunity seems 
to be involved in plaque grown and in its complications (1, 
2). The term endothelial dysfunction indicates a particular 
vascular pathophysiological condition in which endothelial 
cells (ECs), as consequence of several stimuli, shift toward a 
pro atherothrombotic phenotype (3). Unperturbed ECs exert 
several “protective” functions since they modulate vascular 
tone, cellular adhesion, smooth muscle cell proliferation, and 
vessel wall inflammation (4). Importantly, healthy ECs have 
an active role in preventing thrombotic events by secreting 
several antithrombotic substances, such as PAI-1 and TFPI 
(5). However, it has been demonstrated that many stimuli can 
affect these antithrombotic functions of ECs, by modifying their 
gene expression profile and shifting them to a pro-thrombotic 
phenotype (6–11). Similarly, alterations of endothelial healthy 
status, by inducing the loss of its protective function, promote 
atherosclerosis (3). As reported above, several interesting evi-
dence have revealed that, in this complex pathophysiological 
scenario, an important role might be ascribed to the modulation 
of endothelial gene expression (12, 13).
In the last decade, it has been demonstrated that activation 
of the immune system within the plaque should be the major 
determinant of its instability. In fact, unstable coronary plaques 
are infiltrated by macrophages (14), the prototypical cells of 
innate immunity, as well as by a larger quote of T-lymphocytes 
compared to stable plaques (15). T-cells appear to have a pivotal 
role in atherosclerotic plaque evolution because they regulate 
macrophage activity, cell to cell interaction, and production and 
release of cytokines (16), which may finally influence plaque 
vulnerability (17, 18). Indeed, it has been demonstrated that, in 
the clinical setting of acute coronary syndromes (ACS), a local 
cytokine storm, mainly related to Th response, may occur (19). 
Moreover, it has been shown that patients presenting higher 
coronary levels of specific subset of Th-levels and of Th-derived 
cytokines showed a worse disease course (20). Based on the 
available data, it has been suggested that acute coronary events 
might be associated to the local release of cytokines and other 
soluble factors that may influence plaque vulnerability because 
of a direct effect on the cellular components of the lesion. 
In line with these pathophysiological speculations, some studies 
have evaluated changes in gene profile during ACS, looking at 
systemic circulation (21, 22), carotid plaque (23), or platelets 
(24). However, no data are currently available on the effects 
of the soluble mediators released in the coronary circulation 
during the ACS and the gene expression profile in ECs from 
the coronary district. Thus, aim of the present study was to 
evaluate whether serum, and soluble mediators contained in it 
(19), obtained from the coronary circulation of ACS patients 
might cause changes in gene expression profile in coronary 
ECs in  vitro.
MaTerials anD MeThODs
Patient Population
Sixteen patients, divided in two groups, have been enrolled in 
the study. Group I included patients with chronic stable angina 
(SA, n = 4) undergoing elective coronary angiography; group II 
included patients with ACS-non-ST segment elevation myocar-
dial infarction (NSTEMI) (n = 8), undergoing urgent coronary 
angiography and eventually percutaneous coronary intervention 
(PCI) within 24 ± 4 h from ACS diagnosis to avoid confounding 
parameters, mainly related to the timing of blood collection. All 
patients in group I had a history of effort chest pain with a stress 
test positive for inducible myocardial ischemia. ACS was defined 
as indicated in the current guidelines (25) with chest pain at rest 
occurring <48  h from hospital admission with ECG changes 
suggesting myocardial ischemia, with or without increase in 
serum markers of myocardial damage (troponin was measured 
at admission in all patients as standard care). Within the diag-
nosis of ACS, normal or increased serum markers of myocardial 
necrosis defined unstable angina (UA) or NSTEMI, respectively. 
UA was diagnosed in two patients, while the remaining eight 
patients had NSTEMI. Patients with previous myocardial infarc-
tion were excluded as well as patients with ST segment elevation 
myocardial infarction (STEMI) were excluded from the study. 
ACS–STEMI condition is characterized by a thrombotic forma-
tion that completely occludes the vessel with no distal flow. Thus, 
blood collected from coronary sinus (CS) in this condition might 
not be from the culprit vessel. As per protocol design, in both 
groups, only patients with TIMI flow grade ≥2 were included, as 
well as patients with a single vessel disease and a culprit lesion 
located either in the left anterior descending coronary artery or in 
the circumflex coronary artery, both of which drain into the CS.
The protocol was approved by the local ethical committee, and 
all patients gave written informed consent to participate to the 
study.
sample collection
After coronary angiography was performed, and before perform-
ing PCI, a 6  F multipurpose catheter was positioned into the 
CS. To avoid that the different positions of the catheter might 
affect the blood sample, we have checked with angiography its 
position in the CS (Figure S1 and S2 in Supplementary Material). 
Blood samples were simultaneously obtained from the CS and 
the ascending aorta (Ao) and immediately placed into empty pre-
chilled Vacutainer® tubes for serum separation. Blood samples 
were immediately centrifuged at 1,000 × g at 4°C for 20 min, and 
the sera were stored in aliquots at −80°C.
cell culture
Human coronary artery endothelial cells (HCAECs), endothelial 
basal medium-2 (EBM-2), EGM-2-MV SingleQuots, fetal bovine 
serum (FBS), and phosphate-buffered saline (PBS) were purchased 
from Lonza (Viviere, Belgium). HCAECs were maintained in 
EBM-2 supplemented with EGM-2-MV SingleQuots (containing 
vascular endothelial growth factor, basic fibroblast growth factor, 
insulin-like growth factor-I, epidermal growth factor, ascorbic 
TaBle 1 | Demographic characteristics of study population.
group i stable 
angina  
n = 4
group ii (acute coronary 
syndromes–non- sT 
segment elevation 
myocardial infarction) 
n = 8
Age (years) 60 ± 11 63 ± 12
Male sex (%) 2 (50) 4 (50)
# of diseased vessels per patient 1 1
Left anterior descending artery 2 (50) 4 (50)
Circumflex artery 2 (50) 4 (50)
Major risk factors (%)
Hypercholesterolemia 4 (100) 7 (87.5)
Hypertension 4 (100) 8 (100)
Diabetes 2 (50) 4 (50)
Smoking 3 (75) 6 (75)
Medications (at time of angiography)
β-blockers 2 (50) 6 (75)
ACE-Inhibitors 3 (75) 6 (75)
Angiotensin II receptor blockers 1 (25) 2 (25)
Statins 4 (100) 10 (76,9)
Thienopyridines 1 (25) 2 (25)
Aspirin 1 (25) 5 (62,5)
Nitrates 3 (75) 2 (25)
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acid, and gentamicin), and 10% FBS. All cells were cultured at 
37°C in an incubator with a humidified atmosphere and 5% CO2. 
Cells were split at the ratio of 1:3 every passage. Cells from three 
to six passages were used in this study. For experiments, HCAECs 
were grown to confluence, washed with phosphate buffer (PBS), 
and kept in serum-free medium for 24 h to synchronize the cells, 
bringing them all to one phase of cell cycle. Afterward, cells were 
stimulated with medium containing 20% serum collected from 
Ao or CS of ACS or SA patients for 12  h and then total RNA 
was isolated following standard procedure and stored at −80°C 
for further analysis. All experiments have been performed in 
triplicates.
Microarray gene expression analysis
Agilent microarray analyses were done to evaluate the gene 
expression profile in HCAECs exposed to serum obtained 
from CS and Ao of patients with ACS and SA. These experi-
ments were performed using a one color labeling microarray 
system. The quantity of each of the total RNA samples and 
determination of the A260/280  nm ratio was determined by 
spectrophotometry and the size distribution was assessed using 
an Agilent Bioanalyzer. Eight hundred nanogram of total RNA 
were converted into labeled cRNA with nucleotides coupled to 
a fluorescent dye (either Cy3) using the Quick Amp Kit (Agilent 
Technologies, Palo Alto, CA, USA) following the manufacturer’s 
protocol. The A260/280 nm ratio and yield of each of the cRNAs 
were determined using a Thermofisher Nanodrop.
Eight hundred twenty-five nanogram of cRNA-labeled from 
SC or Ao stimulated cells were hybridized to Agilent Human 
Whole Genome 4  ×  44  k Microarrays. The hybridized array 
was washed and scanned, and data were extracted from the 
scanned image using Feature Extraction version 10.2 (Agilent 
Technologies). The raw data and associated sample information 
were loaded and processed by Gene Spring® 11.5X (Agilent 
Technologies). For identification of genes significantly altered in 
patients with UA, total detected entities were filtered by signal 
intensity value (upper cut-off 100th and lower cut-off 20th 
percentile) and flag to remove very low signal entities. Data 
were analyzed using Student’s t-test (p < 0.05) with a Bonferroni 
multiple test correction to minimize selection of false positives. 
Of the significantly differentially expressed RNA, only those with 
greater than twofold increase or twofold decrease as compared to 
controls were used for further analysis. Subsequently, hierarchical 
clustering (condition tree) was applied to the data files. In this 
way, the relationships between the different groups are shown. 
The condition tree was displayed as a heat map, based on expres-
sion levels of the probe sets. Functional and network analyses of 
statistically significant gene expression changes were performed 
using Ingenuity Pathways Analysis (IPA) 8.0 (Ingenuity® Systems, 
http://www.ingenuity.com). Analysis considered all genes from 
the data set that met the twofold (p-value < 0.05) change cut-off 
and that were associated with biological functions in the Ingenuity 
Pathways Knowledge Base. The significance of the association 
between the data set and the canonical pathway was measured in 
two ways: (1) ratio of the number of genes from the dataset that 
map to the pathway divided by the total number of genes that map 
to the canonical pathway is displayed and (2) Fisher’s exact test 
was used to calculate a p-value determining the probability that 
the association between the genes in the dataset and the canonical 
pathway is explained by chance alone.
real-time Pcr
Real-time PCR has been performed on selected target genes. 
Following the manufacturer’s instructions, total RNA was 
extracted from HCAECs exposed to serum obtained from CS 
of patients with unstable and SA by using the RNAeasy Micro 
Kit (QIAGEN). The RNA obtained was treated with DNAase I 
to eliminate possible genomic DNA contamination. cDNA was 
synthesized with High-Capacity cDNA reverse transcription kits 
(Applied Biosystems). Total RNA (10  µL) was reversely tran-
scribed in a total volume of 20 µL, containing 25× dNTP Mix 
(100 mM) 0.8 µL, 10× RT random Primers 2 µL, 10 × RT buffer 
2  µL, MultiScribe reverse transcriptase 1  µL, RNase inhibitor 
1 µL, DEPC free H2O add up to 3.2 μL. The reaction was run at 
25°C for 10 min, 37°C for 120 min; 85°C for 5 min. The cDNA 
was stored at −20°C.
IL-17A, IL8, IL10, phospholipase C-beta 4 (PLCB4), PLA2 IIa, 
and PGE2genes were amplified by real-time PCR from mRNA 
using appropriate primers to detect their expression in HCAECs 
exposed to sera obtained from CS of patients with ACS or SA, 
respectively (Table S1 in Supplementary Material).
Real-time PCR and data analysis were performed using 
96-microwell plates and a Biorad detector (Biorad). Two hun-
dred nanogram of purified DNA, 5 µL of 5× Hot TaqEvaGreen 
(Microtech), and 250 nM of primers were added to each micro-
well to reach a total volume of 20 µL per well, DNase-RNase-free 
distilled water (Sigma) was added. The reaction was run at 95°C 
for 15 min, followed by 40 cycles at 95°C for 15 s, 60–65°C for 
20 s and 72°C for 20 s. Three housekeeping genes were used as a 
TaBle 2 | Upregulated genes in hcaecs stimulated with serum from cs 
of acute coronary syndromes patients.
gene 
symbol
gene name p-Value Fold 
change
SELE Selectin E 3.01E−10 19.661016
CXCL1a Chemokine (C–X–C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha)
1.05E−19 8.485691
CXCL2 Chemokine (C–X–C motif) ligand 2 3.95E−25 6.6117725
CCL2a Chemokine (C–C motif) ligand 2 2.75E−20 6.3248153
PTGS2a Prostaglandin-endoperoxide synthase 
2 (prostaglandin G/H synthase and 
cyclooxygenase)
3.53E−28 5.8133426
CD86 CD86 molecule 1.34E−06 4.9321218
RELB v-Rel reticuloendotheliosis viral 
oncogene homolog B
1.63E−20 4.7633815
FOSB FBJ murine osteosarcoma viral 
oncogene homolog B
4.75E−15 4.325817
NFKBIA Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
inhibitor, alpha
3.81E−17 4.0123706
JUNBa Jun-B protoncogene 1.07−08 3.95
ID1 Inhibitor of DNA binding 1, dominant 
negative
1.14E−15 3.679152
NFKBIZ Nuclear factor of kappa light 
polypeptide
5.64E−23 3.3618975
FOS FBJ murine osteosarcoma viral 
oncogene homolog
1.12E−16 3.2505574
FGF18 Fibroblast growth factor 18 5.17E−12 3.2300966
IL7R Interleukin 7 receptor 8.03E−07 3.1095386
ADAMTS1 ADAM metallopeptidase with 
thrombospondin type 1 motif, 1
4.85E−20 3.1251428
CD83 CD83 molecule 2.72E−12 2.8649588
IL8a Interleukin 8 1.22E−17 2.8357644
IL11 Interleukin 11 4.98E−11 2.8224506
CXCL3 Chemokine (C–X–C motif) ligand 3 2.48E−13 2.7130814
ICAM1 Intercellular adhesion molecule 1 1.46E−20 2.6648185
FOSL2 FOS-like antigen 2 7.37E−21 2.5525434
TRAF1 TNF receptor-associated factor 1 1.02E−09 2.4518566
NFKBIE Nuclear factor of kappa light 
polypeptide
4.15E−24 2.3899362
VEGFA Vascular endothelial growth factor A 1.12E−14 2.3613784
HBEGF Heparin-binding EGF-like growth factor 1.68E−18 2.3418474
RASSF8a Ras association domain family 6.72E−06 2.34
MAP3K8 Mitogen-activated protein kinase kinase 
kinase 8
2.69E−16 2.270313
IL3RA Interleukin 3 receptor, alpha (low affinity) 2.29E−10 2.2516959
VASP Vasodilator-stimulated phosphoprotein 7.61E−08 2.2024417
IL6 Interleukin 6 1.44E−08 2.20
GPR68 G protein-coupled receptor 68 0.0041 2.16986
BMPR1B Bone morphogenetic protein receptor, 
type IB
5.94E−05 2.12
FBLN1 Fibulin 1 3.95E−07 2.1075332
RASL10Aa RAS-like, family 10, member A 2.60E−13 2.10
PF4 Platelet factor 4 0.0043 2.0621264
aGene involved in IL-17 signaling.
FigUre 1 | gene expression measured in human coronary artery 
endothelial cells stimulated with serum from aorta and coronary 
sinus of patients with acute coronary syndromes (acs) and stable 
angina (sa). Upregulated (684) genes are represented in green and 
downregulated (283) are represented in red (difference ≥2-fold, or ≤-2-fold 
were measured). All microarray data are registered in GEO platform with the 
following code GSE54977 (different gene expression profile in ACS patients 
compared to SA patients), and are available at the link: http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE54977.
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control following the latest MIQE guidelines (26). The specificity 
of the amplification products was controlled using a melting curve 
analysis. The copy number of IL-17A, IL-8, IL-10, PLCB4, PLA2 
IIa, prostaglandin E2 (PGE2), and housekeeping transcripts in 
samples was calculated with the Bio-Rad CFX Manager software 
according to corresponding standard curves. All samples were 
measured in triplicate. Data are presented as mean  ±  SEM. 
Differences between groups were determined by a one-way 
ANOVA followed by a Student’s t-test with Bonferroni’s correc-
tion. A p-value < 0.05 was considered statistically significant.
resUlTs
Patient Population
Clinical characteristics of the patients enrolled are reported in 
Table 1.
Microarray gene Profile
The expression profile of ACS-related genes was determined 
by comparing gene expression in HCAECs exposed to serum 
collected from Ao and CS of patients with SA. To exclude that 
serum exerted direct toxic effects on HCAECs, trypan blue exclu-
sion assays were performed at conclusion of the incubation and 
demonstrated >95% viability with no differences between the 
different experimental groups (data not shown).
As expected, serum obtained from the Ao of ACS patients did 
not determine any significant change in gene expression profile 
TaBle 3 | Downregulated genes in hcaecs stimulated with serum from 
cs of acute coronary syndromes patients.
gene 
symbol
gene name p-Value Fold 
change
CXCR4 Chemokine (C–X–C Motif) receptor 4 3.44E−26 −4.4
IL 10 Interleukin 10 2.63E−0.7 −4.15
CCNG2 Cyclin G2 4.98E−12 −3.5
CDKN1B Cyclin-dependent kinase inhibitor 1B 6.43E−24 −2.95
CFH Complement factor H 2.68E−13 −2.59
IL 33 Interleukin 33 2.39E−12 −2.43
NAMPT Nicotinamide phosphoribosyltransferase 6.88E−07 −2.15
TBET T-cell-specific T-Box transcription factor 
T-Bet
1.01E−11 −2.14
STAT1 Signaling transducer and activator of 
transcription-1
1.36E−11 −2.12
RAB5A RAB5A, member RAS oncogene family 5.37E−20 −2.09
CCNG1 Cyclin G1 2.43E−11 −2.04
SENP7 SUMO1/sentrin specific peptidase 7 1.30E−07 −2.04
IL 5 Interleukin 5 3.74E−08 −2.03
VLDLR Very low density lipoprotein receptor 1.18E−12 −2.01
TNFSF10 Tumor necrosis factor (ligand) superfamily, 
member 10
4.68E−15 −2.00
TaBle 4 | Upregulated pathways in hcaecs stimulated with serum from 
cs of acute coronary syndromes patients.
PaTWaYs p-Value
TNRF2 signaling 9.32E−6
CD40 signaling 9.07E−4
NFkB signaling 8.14E−3
IL17 signaling 7.29E−4
Glucocorticoid receptor signaling 6.13E−4
B cell activating factor signaling 5.9E−3
MIF regulation of innate immunity 5.38E−3
Dendritic cell maturation 5.11E−3
Factors promoting cardiogenesis in vertebrates 5.11E−3
TGFB signaling 5.00E−4
PKCθ signaling in T lymphocytes 4.92E−2
April mediated signaling 4.9E−3
MSP-RON signaling pathway 4.86E−2
Communication between innate and adaptive immune cells 4.81E−2
Protein kinase A signaling 4.52E−2
Cardiomyocytes differenziation via BMP receptor 3.99E−3
Granzyme A signaling 3.76E−2
IL 8 signaling 3.74E−2
HMGB1 signaling 3.39E−4
Hyproxia signaling in the cardiovascular system 3.08E−2
TREM1 signaling 2.96E−3
TWEAK signaling 2.92E−3
RAR activation 2.91E−3
PI3K signaling in B lymphocytes 2.88E−2
Lymphotoxin B receptor signaling 2.01E−2
BMP signaling 1.98E−3
MIF-mediated glucocorticoid regulation 1.85E−2
TNRF1 signaling 1.59E−3
4-IBB signaling in T-lymphocytes 1.54E−2
ATM signaling 1.47E−2
CD 27 signaling in lymphocytes 1.38E−2
TaBle 5 | Downregulated pathways in hcaecs stimulated with serum 
from cs of acute coronary syndromes patients.
Pathways p-Value
OX40 signaling 4.75E−2
PI3K/AKT signaling 4.39E−2
G α 12/13 signaling 4.39E−2
Toll-like receptor signaling 4.39E−2
Regulation of IL2 expression in activated and anergic T-Lymphocytes 4.22E−2
TIGHT junction signaling 4.11E−2
CD28 signaling in T-helper cells 3.99E−2
B-cells signaling 3.19E−2
Erythropoietin signaling 2.89E−2
ILK signaling 2.75E−2
IL 10 signaling 2.51E−2
FGF signaling 1.35E−2
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as compared to serum obtained from the Ao of SA patients. 
In   contrast, serum collected from the CS of patients with ACS 
caused a significant change in gene expression profile with 
respect to CS serum samples from patients with SA (Figure 1). 
Specifically, only genes with twofold increase or decrease were 
considered significant (Tables 2 and 3). Among the differentially 
expressed genes, 684 were upregulated and 283 downregulated 
(Figure  1). The genes with a statistically significant variation 
underwent to functional and network analyses using IPA 8.0.
The E-selectin (SELE) gene was the most upregulated one, fol-
lowed by Chemokine (C–C motif) ligand 2 (CCL2), Chemokine 
(C–X–C motif) ligand 1 (CXCL1), and prostaglandin G/H synthase 
and cyclooxygenase (PTGS2) genes. Analysis of the upregulated 
genes in HCAECs stimulated with CS serum from ACS patients 
were associated with the following pathways: TNF receptor-2 
signaling, CD40 signaling, NFKB signaling, glucocorticoid recep-
tor signaling, B cell activating factor signaling, MIF regulation of 
innate immunity, dendritic cell maturation, factors promoting 
cardiogenesis in vertebrate, TGF-beta signaling, PKCθ signaling 
in T lymphocytes, April-mediated signaling, cardiomyocyte dif-
ferenzation via BMP receptor, granzyme A signaling, IL8 signal-
ing, HMGB1 signaling, hypoxia signaling in the Cardiovascular 
System, TREM1 signaling, TWEAK signaling, RAR activation, 
PI3K signaling in B lymphocytes, lymphotoxin in B receptor 
signaling, BMP signaling, MIF-mediated glucocorticoid regula-
tion, TNRF1 signaling, 4-IBB signaling in T Lymphocytes, ATM 
signaling, and CD27 signaling in Lymphocytes (Table 4). On the 
contrary, in the same experimental set-up the downregulated 
genes were associated with the following pathways: OX40 signal-
ing, PI3K/AKT signaling, G α 12/13 signaling, Toll-like receptor 
signaling, regulation of IL2 expression in activated and anergic 
T lymphocytes, TIGHT junction signaling, CD28 signaling in 
T-helper cells, B-cells signaling, erytropoietin signaling, ILK 
signaling, IL10 signaling, FGF signaling (Table 5).
Analysis of the downregulated genes revealed that the most 
modulated ones were the Chemokine (C–X–C motif) receptor 4 
(CXCR4) and the IL-10.
Interestingly, a subanalysis of the upregulated genes revealed 
that a cluster of them was associated with the pathways of IL-17 
Signaling (Figure 2): chemokine (C–C motif) ligand 2 (CCL2), 
chemokine (C–X–C motif) ligand 1 (CXCL1), interleukine 8 
(IL8), Janus kinase 1, v-Ki-ras2 Kirsten rat sarcoma viral onco-
gene homolog, muscle RAS oncogene homolog, prostaglandin-
endoperoxide synthase 2, prostaglandin G/H synthase and 
cyclooxygenase (PTGS2) as shown in Table 3 and Figure 2.
FigUre 2 | (a) Heat map of human coronary artery endothelial cells stimulated with serum obtained from coronary sinus of patients with acute coronary syndromes 
and normalized with human coronary endothelial cells incubated with serum obtained from aorta of the same patients. (B) Heatmap of IL-17 pathway (p = 7.29E−4) 
obtained after Ingenuity Pathways Analysis.
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real-time Pcr
Since we have previously demonstrated that Th-17 and its 
derived interleukin, IL-17, might be involved in the ACS patho-
physiology (20), we pointed out our attention on this specific 
pathway.
Real-time PCR experiments were performed to evaluate the 
expression of several genes belonging to the IL-17 pathway. 
Specifically, the levels of IL-17A, which is mainly produced by 
Th17 cells, as well as the levels of phospholipase A2 (PLA2 IIa), 
PLCB4 and their product PGE2 levels, involved in the activation 
of Th17 cells, were measured. In HCAECs stimulated with 
serum from the CS of ACS patients a significant increase of RNA 
levels for IL-17A, PLA2 IIa, PLCB4, and PGE2 was observed 
as compared to cells stimulated with serum from SA patients 
(Figures 3 and 4). Moreover, the levels of IL-8 were increased 
(Figure 3).
Real-time PCR was performed to evaluate the levels of 
expression of CXCR4 and IL-10, the most downregulated genes. 
Interestingly, in HCAECs stimulated with serum from CS of ACS 
patients, levels of expression for these genes were significantly 
FigUre 4 | gene expression of Pla-iia (a), prostaglandin e2 (B), and 
phospholipase c-beta 4 (c), in human coronary artery endothelial 
cells stimulated for 12 h with serum obtained from coronary sinus (cs) 
of patients with acute coronary syndromes, or from cs of patients 
with stable angina determined by real-time Pcr analysis. Data are 
expressed as the mean ± SEM of 3 independent experiments (*p < 0.05).
FigUre 3 | gene expression of il-17a (a) and il-8 (B) genes in human 
coronary endothelial cells stimulated for 12 h with serum obtained 
from coronary sinus (cs) of patients with acute coronary syndromes, 
or from cs of patients with stable angina determined by real-time 
Pcr analysis. Data are expressed as the mean ± SEM of three independent 
experiments (*p < 0.05).
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lower as compared with the expression measurable in cells stimu-
lated with serum from CS of SA patients (Figure 5).
DiscUssiOn
In the present study, we show that sera collected from the CS 
of ACS patients, which resemble coronary circulation, induce a 
strong modulation at gene levels in human coronary endothelial 
cells, which results in upregulation of 684 genes and downregula-
tion of 283 genes, as compared to cells stimulated with sera from 
SA patients. On the contrary, sera collected from the Ao of 
these patients, which resemble the systemic circulation, do not 
determine any significant change in gene expression profiles in 
human ECs compared to patients with SA. These results suggest 
that, during an acute event, in the coronary circulation there are 
“local” factors able to affect gene expression profile of coronary 
ECs. These changes of endothelial gene profile seem associated 
with modulation of cellular pathways that might facilitate the 
progression of coronary atherosclerosis and lead to acute com-
plications such as acute coronary events.
We have observed upregulation of many genes that are known 
to be involved in the early steps and in the progression of ath-
erosclerosis. Specifically, SELE, the most upregulated gene, is a 
glycoprotein actively involved in the first steps of atherosclerosis 
since it sustains the leukocytes adhesion to endothelial wall and 
their passage to the subendothelial space (27, 28). Moreover, 
we observed the upregulation of genes that codify for several 
chemokines such as PTGS2, CCL2, and CXCL1 and 2, that, in 
response to pro-inflammatory cytokines, promotes the recruit-
ment of other effector cells, such as monocytes, granulocytes, 
and T cells-effector, actively involved in the progression of ath-
erosclerosis (29–31). Furthermore, other upregulated genes were 
those of the pro-inflammatory interleukins IL3RA, IL7R, IL8, 
IL11, usually secreted by immune system cells, and of the NF-κB 
family (NF-κBIA, NF-κBIZ, NF-κBIE), nuclear transcription fac-
tors known to be involved in the development of atherosclerosis 
(32, 33). Again, many other upregulated gene in coronary ECs, 
such as PTGS2, fibroblast growth factor 18 (FGF18), vascular 
FigUre 5 | gene expression of il-10 (a), cXcr4 (B), in human 
coronary artery endothelial cells stimulated for 12 h with serum 
obtained from coronary sinus (cs) of patients with acute coronary 
syndromes, or from cs of patients with stable angina determined by 
real-time Pcr analysis. Data are expressed as the mean ± SEM of three 
independent experiments (*p < 0.05).
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endothelial growth factor A (VEGF-A), intercellular adhesion 
molecule 1 (ICAM1), or platelet factor 4 (PF4), are selectively 
involved in the inflammatory pathways as mechanisms respon-
sible of atherosclerosis (34–37).
We have recently demonstrated that a cytokine storm occurs 
in the coronary circulation of patients with ACS, reflecting 
mainly a Th1 response (19). Moreover, we have shown that 
ACS patients with higher levels of Th17, a separate CD4+ T cell 
subset distinct from Th1, Th2, had a worse clinical outcome, 
suggesting that these T cells might be actively involved in ACS 
pathophysiology (20). In line with these previous observations, 
in the present report, we indicate that, in HCAECs stimulated 
with serum from CS of ACS patients, among several upregulated 
genes, some of them were associated with the pathways of 
IL-17. Here, we demonstrate that levels of gene expression for 
IL-17A that is mainly produced by Th17 cells are elevated in 
HCAECs stimulated with serum from coronary circulation of 
ACS patients. The IL-17A receptor is ubiquitously expressed 
and the cytokine has several complex activities: it promotes 
the production of TNF- β, IL-1 β, and MCP-1 as well as of 
adhesion molecules like ICAM1 (38, 39). Several studies already 
showed that the IL-23/IL-17 axis acts as a bridge between the 
innate and the adaptive immune system (40). Specifically, IL-17 
is involved in the response against extracellular bacteria and 
fungi regulating neutrophil recruitment and activation, and it 
is essential in infectious and autoimmune diseases pathogenesis 
(41). In the cardiovascular system, IL-17A, by acting on several 
cell populations actively involved in pathophysiology of athero-
thrombosis such as macrophages and monocytes, or normally 
represented in the vascular wall, such as endothelial and smooth 
muscle cells, is able to induce a pro-inflammmatory status, 
thrombosis and to destabilize plaque (41). Moreover, elevated 
levels of IL-17A expression have been detected in ruptured or 
lipid-rich plaques (42).
Besides evaluating gene expression for IL-17A, that is mainly 
produced by Th17 cells, we have measured the expression of some 
cytokines involved in Th17 cells activation such as PLA2 IIa, 
PLCB4 and their product PGE2 (43–45). In HCAECs stimulated 
with serum from CS of ACS patients, we observed the significant 
increase of gene expression for PLA2IIa, PLCB4 and PGE2 as 
compared to cells stimulated with serum from CS of AS patients. 
Taken together, and in line with previous reports about the role of 
Th-17/IL-17 in ACS pathophysiology (19, 46), these results sug-
gest a potential relationship between changing of HCAECs gene 
profile in response to inflammatory stimuli and future coronary 
events. Specifically, dysfunctional ECs might themselves produce 
IL-17 and, at the same time, significantly enhance Th-17 response 
in the coronary circulation, finally creating a pro-atherothrom-
botic milieu.
Another interesting finding was that in HCAECs stimulated 
with CS sera from ACS patients, a significant downregulation 
of IL-10 gene was observed. Interleukin 10 is a kind of an anti-
inflammatory cytokine which can reduce the formation of ath-
erosclerosis and maintain the stability of atheromatous plaques, 
which play an important role in inhibiting the occurrence of ACS 
(46–48). Thus, these protective, anti-inflammatory properties of 
IL-10 seem to be significantly reduced in ECs as consequence 
of soluble mediators contained in the sera from the coronary 
circulation of ACS patients.
Finally, we have found that, in HCAECs stimulated with 
serum form ACS patients, the levels of CXCR4 expression were 
significantly lower than those measurable in cells stimulated with 
serum from SA patients. CXCR4 is a receptor for the chemokine 
CXCL12 (also known as stromal cell derived factor-1, SDF-1), 
widely and constitutively expressed by hematopoietic and ECs 
(49). The SDF-1/CXCR-4 pathway is a prerequisite of embryonic 
vasculogenesis, and induction of SDF-1 expression seems to 
have a major role in initiating revascularization of the ischemic 
injured tissues (50, 51). Thus, it might be speculated that soluble 
mediators released in the coronary circulation during an ACS, by 
reducing CXCR4 expression in ECs, might affect also the mecha-
nisms involved in myocardial revascularization and, specifically, 
the healing of the injured vessel.
Potential limitations of the Present study
Some potential limitations should be taken in account in evaluat-
ing the results of the present study. First, the number of patients 
might be considered too small, however, this is a research study 
with pathophysiological aims. Thus, for such experimental stud-
ies, we do need of a small, but statistically significant number of 
observations. Another potential limitation is that, in addition to 
taking serum, it would be useful to perform also flow cytometric 
analysis of T-cell immunity in order to correlate the results with 
immune function. Indeed, patients of the present study have 
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been already studied in their immunological profile in a previous 
report from our research group (19). Specifically, the present 
study has been performed by selecting those patients with highest 
trans-coronary levels of Th17/IL-17.
cOnclUsiOn
Results of the present study, with all potential limitations derived 
from an in vitro study, highlight how, during an acute event, the 
chemical mediators released in the coronary circulation might 
be able to perturb coronary ECs modifying their gene profile. 
These modified ECs, through downregulation of protective gene 
and, mainly, through upregulation of gene able to modulate the 
Th-17/IL-17 pathway, might play a key role in progression of 
coronary atherosclerosis and in developing future acute events 
(Figure  6). Although further studies are required to confirm 
these findings in clinical settings, this study contributes to shed 
a brighter light on the complex relationship between ECs and 
immunity in the coronary district in the complex scenario of 
ACS pathophysiology.
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FigUres s1 and s2 | Positioning of the 6 F multipurpose catheter into 
the coronary sinus.
TaBle s1 | Primers sequence.
FigUre 6 | schematic view of gene expression profile in endothelial cells (ecs) and possible interaction with T-cells. Soluble mediators released in 
coronary circulation of acute coronary syndromes patient modulate changes of gene expression profile in coronary ECs. Several genes are upregulated, causing a 
local increase of of some cytokines. IL-17 may induce differentiation of naive T-cells into Th-17cells, thus promoting plaque destabilization. Similarly, increased 
expression of phospholipase C-beta 4, PLA-IIA, and prostaglandin E2 enhance coronary endothelial dysfunction and local Th-17 recruitment. Moreover, high levels 
of IL-8 induce atherosclerotic lesion formation. Conversely, other genes are downregulated with decreased levels of the protective chemical mediators such as the 
anti-atherosclerotic cytokine IL-10, and the CXC-R, involved in vessel healing.
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